Login to Your Account



Biosimilars Market Grows 20%

Oncobiologics, Zhejiang Huahai Form Global Alliance

By Catherine Shaffer
Staff Writer

Thursday, May 9, 2013

Oncobiologics Inc. allied with Zhejiang Huahai Pharmaceutical Co. Ltd. to develop, manufacture and commercialize biosimilar monoclonal antibody products equivalent to Humira, Rituxan, Avastin and Herceptin in a rapidly expanding subsector which has reached $2.4 billion – a 20 percent increase from 2012.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription